Support Program for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if support, such as text reminders or phone counseling, can help breast cancer patients adhere to their endocrine therapy medication plan. The study includes different groups: some will receive text reminders, others phone counseling, some both, and another group will follow the usual care routine with educational materials. It targets women diagnosed with early-stage, hormone receptor-positive breast cancer who have recently started endocrine therapy. Participants must be comfortable using a smartphone for study-related activities. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Do I have to stop taking my current medications for the trial?
The trial does not specify whether you need to stop taking your current medications. However, it focuses on ensuring you take your prescribed endocrine therapy medication as directed.
What prior data suggests that this support program is safe for breast cancer patients?
Research has shown that text message reminders (TMR) effectively and safely help people manage their health. These reminders assist in handling chronic diseases, with no evidence of harm. Studies have also demonstrated that motivational interviewing (MI) is safe. This method involves conversations that encourage positive changes in health habits. It has been used safely across various health settings, showing improvements without negative effects. The combination of TMR and MI also appears safe, aiming to enhance health by reminding and encouraging patients. No reports of harm have emerged from using both methods together, suggesting these strategies are well-tolerated and safe for patients.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores innovative ways to enhance adherence to endocrine therapy (ET) for breast cancer patients. Unlike standard care, which typically involves regular clinic visits and provides general educational resources, this trial tests personalized support strategies. Arm I offers daily text reminders and monthly check-ins to keep patients on track with their medication. Arm II adds a human touch with motivational interviewing sessions via phone to help patients set and achieve health goals. Arm III combines both approaches for a comprehensive support system, potentially leading to better medication adherence and improved outcomes for breast cancer survivors.
What evidence suggests that this trial's support program could be effective for improving medication adherence in breast cancer patients?
Research has shown that text message reminders can greatly help patients stick to their healthcare routines. In this trial, participants in Arm I will receive daily text message reminders to take their ET medication, which studies have found to increase adherence. Participants in Arm II will engage in motivational interviewing, a method effective in lowering anxiety and depression while boosting patients' confidence in managing their health. Arm III combines both text reminders and motivational interviewing, potentially further improving medication adherence, as evidence suggests these methods work well together to support treatment plans.36789
Who Is on the Research Team?
Katherine E. Reeder-Hayes, MD
Principal Investigator
University of North Carolina, Chapel Hill
Are You a Good Fit for This Trial?
This trial is for breast cancer patients who've had surgery or other treatments, except reconstruction. They must have hormone receptor positive, HER2-neu negative cancer and started endocrine therapy within the last 6 months or plan to start within 6 weeks after joining. Participants need a smartphone for study activities.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive online educational information about ET and are randomized to receive text message reminders, motivational interviewing counseling, or both for up to 9 months
Follow-up
Participants are monitored for ET adherence and overall health for up to 24 months post-randomization
What Are the Treatments Tested in This Trial?
Interventions
- Additional Support Program Via Text Messaging and Telephone-Based Counseling
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborator